about
The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosisInterleukin-7-mediated inflammation in unstable angina: possible role of chemokines and plateletsIncreased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammationToll-like receptor 9-activation during onset of myocardial ischemia does not influence infarct extensionIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureThe early transcriptomic response to interleukin 1β and interleukin 33 in rat neonatal cardiomyocytesMyocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice.Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathyLack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overloadToll-like receptor 9 mediated responses in cardiac fibroblastsThe homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure.The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling.CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.Association of ficolin-3 with severity and outcome of chronic heart failure.Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.Therapeutic potential of anticytokine therapy in congestive heart failure.Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammationSustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO MiceAgents targeting inflammation in heart failure.Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications.Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.Inflammation in coronary artery disease: potential role for immunomodulatory therapy.Anti-inflammatory trials in chronic heart failure.Systemic inflammation in heart failure--the whys and wherefores.The role of intravenous immunoglobulin in the treatment of chronic heart failure.Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation.Role of inflammation in the progression of heart failure.Potential mechanisms of benefit with thalidomide in chronic heart failure.NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis.The role of statins in heart failure.The complex role of T-cell-based immunity in atherosclerosis.Chemokines and cardiovascular risk.Activated platelets and atherosclerosis.
P50
Q28083548-EEDED5A9-B195-492D-8862-91C58FE3DF6EQ28195974-33D7F7AF-DD09-42AB-87DA-082858AFD14AQ28200764-2ECCEF20-009D-4D3D-BC54-B8420CA267D8Q28541982-8A3D21F4-6E75-4008-90B7-BC1C35DAE720Q28575465-CDFF5A51-3AE3-441C-8B1C-CA27982C29B9Q28578898-9810B08F-B942-4D88-BBC4-FCB538DCF500Q30611192-853DF63A-650B-49DB-808F-7DBD83D54287Q31152172-7E697997-3752-4B21-B01B-22F315F8EE75Q33383387-45263AD3-C1CB-4040-A359-C8734C110602Q33604761-BE25875A-4440-4C59-BF24-FC5FE7DFDC5EQ33799421-9F58AECB-09C6-4AE0-B135-09117E7E4218Q33886486-8A05EE5A-5BF3-46D9-AA09-15100E094026Q34050642-7A686F68-747D-48AF-BA7A-8E7B01BF4E36Q34200352-11068040-0204-4C57-A5FD-C82CB8040D37Q34277432-90A77A35-62B0-4445-8AAA-219B3F2D9F36Q34513415-1B11CD1D-3A6A-4B19-8DB5-D681122A9613Q34619812-C229A3C1-ED4D-45E4-865C-68534A3007E5Q34676160-34E2AEF3-497E-4C6E-9216-E00A5ADD6922Q35406034-4CC0B1A7-64CB-484F-8D11-B8934347DE05Q35553707-DC7A25C2-5734-4FFA-ACA9-3D7C289A7216Q35750462-78E2D2B6-E99D-4DE1-870D-535528445920Q35756990-B732BB3E-60DF-442E-852E-45E6BFAB7089Q35768272-5342A16F-226A-44D5-9460-1ED3F0A1ABDBQ35797015-26FA7CFB-FF40-4206-9FA9-5DB2BAEA7B0FQ35804806-473A4817-0690-4F8D-9963-EFD0338F6C93Q36145827-0B36E2EE-DE58-406E-8BA7-22B7F68D5B51Q36198484-6448543A-3F47-49D7-B8C3-888CA5D0C65CQ36283698-6880AB0C-1E8E-40C6-A59F-A8289EB65614Q36314881-9F82BA53-6B88-4E7B-BEF4-AA80AFC504D1Q36425459-0B126623-1F12-4654-8093-8C7D85E02B77Q36526913-6AD7370C-8977-4696-841E-957A1712361AQ36558817-B8F8B02C-A4DB-4DE2-9AA1-9F9F352874AEQ36752011-1F1E8D5A-1301-4652-8A4E-81F9DCB2B3B8Q36806972-A26E04E9-D80B-4A9B-85BA-89972EE7BB82Q36822365-146888DB-B597-44E1-A11F-06BB6B0A8D7BQ36956703-F3428800-90AD-4697-86D3-56645810B9F8Q37000806-4057DDA0-3ED3-4569-A8B1-D9BA4D991DD3Q37167783-F01BC234-6DB3-4866-AB3D-ACA49DEEAA52Q37231421-A6D6940C-C9AF-4A34-8083-D2DF7D2EAE63Q37786647-C2C1FAF8-62F7-4AE4-B7BA-2845C86CA89C
P50
description
Noors onderzoeker
@nl
Norwegian researcher
@en
norsk forsker
@nb
taighdeoir Ioruach
@ga
name
Arne Yndestad
@ast
Arne Yndestad
@da
Arne Yndestad
@de
Arne Yndestad
@en
Arne Yndestad
@es
Arne Yndestad
@fr
Arne Yndestad
@ga
Arne Yndestad
@nb
Arne Yndestad
@nl
Arne Yndestad
@nn
type
label
Arne Yndestad
@ast
Arne Yndestad
@da
Arne Yndestad
@de
Arne Yndestad
@en
Arne Yndestad
@es
Arne Yndestad
@fr
Arne Yndestad
@ga
Arne Yndestad
@nb
Arne Yndestad
@nl
Arne Yndestad
@nn
prefLabel
Arne Yndestad
@ast
Arne Yndestad
@da
Arne Yndestad
@de
Arne Yndestad
@en
Arne Yndestad
@es
Arne Yndestad
@fr
Arne Yndestad
@ga
Arne Yndestad
@nb
Arne Yndestad
@nl
Arne Yndestad
@nn
P106
P21
P214
512149106276768492248
P2287
P27
P31
P496
0000-0003-0855-1379
P6634
arne-yndestad-23b35278
P734
P735
P7859
viaf-512149106276768492248